Eliquis approved for DVT and PE

Eliquis (apixaban) is now licensed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults.

Eilquis (apixaban) can be used instead of combination warfarin and a low molecular weight heparin for the treatment of pulmonary embolism (pictured). | SCIENCE PHOTO LIBRARY
Eilquis (apixaban) can be used instead of combination warfarin and a low molecular weight heparin for the treatment of pulmonary embolism (pictured). | SCIENCE PHOTO LIBRARY

Patients being treated for acute DVT or PE should receive apixaban 10mg twice for the first 7 days, followed by 5mg twice daily.

The recommended dose for the prevention of recurrent DVT or PE in adults is 2.5mg twice daily, following 6 months of apixaban at the treatment dose or another conventional anticoagulant.

Apixaban is not recommended for haemodynamically unstable PE or patients who require thrombolysis or pulmonary embolectomy, and for patients with active cancer.

Mechanism of action

Apixaban directly inhibits factor Xa, thereby preventing thrombin formation and clot development. Like rivaroxaban and dabigatran, it does not require routine anticoagulation monitoring.

Clinical studies

In the double-blind 12-month AMPLIFY trial, apixaban was non-inferior to enoxaparin/warfarin for the prevention of recurrent VTE/VTE-related death, and was associated with a lower risk of major bleeding (RR 0.31, 95% CI 0.17–0.55, p<0.0001).

In the double-blind, placebo-controlled 12-month extension trial AMPLIFY-EXT (n=2486), patients treated with apixaban had a significantly lower rate of recurrent VTE/all-cause death than those given placebo (1.7% vs 8.8%, p<0.001) and rates of major bleeding did not differ significantly between the groups.

Other indications

This latest indication update means that the licensed indications of Eliquis are now the same as those of Xarelto (rivaroxaban) and Pradaxa (dabigatran).

View Eliquis drug record

Further information: BMS

Follow MIMS on Twitter

Sign up for MIMS bulletins


Read these next

NICE approves apixaban for treatment of DVT and pulmonary embolism

NICE approves apixaban for treatment of DVT and pulmonary embolism

Patients can be given apixaban (Eliquis) on the NHS...

NICE recommends dabigatran as an option in thromboembolism

NICE recommends dabigatran as an option in thromboembolism

NICE has recommended that dabigatran etexilate (Pradaxa)...

Xarelto: first novel anticoagulant licensed for ACS

Xarelto: first novel anticoagulant licensed for ACS

Bayer has launched a new 2.5mg strength of Xarelto...

Pradaxa now indicated for DVT and PE

Pradaxa now indicated for DVT and PE

Pradaxa (dabigatran) is now licensed for the treatment...

Xarelto licensed to treat pulmonary embolism

Xarelto licensed to treat pulmonary embolism

Xarelto (rivaroxaban) can now be prescribed for the...

NICE approves rivaroxaban for DVT and recurrent VTE

NICE approves rivaroxaban for DVT and recurrent VTE

The direct factor Xa inhibitor rivaroxaban has been...

NICE approves dabigatran in atrial fibrillation

NICE approves dabigatran in atrial fibrillation

Dabigatran etexilate (Pradaxa) can now be prescribed...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.